News
PERCF
0.0050
NaN%
--
Percheron Therapeutics Updates Market on Lapse of 600,000 Options
TipRanks · 04/30 23:23
Percheron Therapeutics Issues 131 Million Unquoted Options at $0.01 Exercise Price
TipRanks · 04/21 23:43
Percheron Therapeutics Seeks ASX Quotation for 262.9 Million New Shares
TipRanks · 04/21 23:29
Percheron’s VISTA-Targeting Cancer Drug Clears Key Phase I Safety Hurdle
TipRanks · 04/20 22:45
Percheron Therapeutics Corrects ASX Filing on Unquoted Equity Securities
TipRanks · 04/15 02:05
Percheron Director Increases Stake Through Entitlement Offer
TipRanks · 04/15 01:37
Percheron Therapeutics Issues 86 Million Unquoted Options Expiring 2028
TipRanks · 04/15 01:23
Percheron Therapeutics Seeks ASX Quotation for 172 Million New Shares
TipRanks · 04/15 01:22
Percheron Raises $2.2m to Advance HMBD-002 Towards Phase II Trial
TipRanks · 04/14 03:13
Percheron Sets Closing Date for Entitlement Offer to Fund Therapeutic Pipeline
TipRanks · 04/02 00:13
Percheron to Showcase New HMBD-002 Cancer Data at ASCO 2026
TipRanks · 03/30 22:06
Percheron Therapeutics Launches Discounted Entitlement Offer, Excludes Overseas Holders
TipRanks · 03/23 21:52
Percheron Therapeutics Launches Non-Renounceable Entitlement Offer With Free-Attaching Options
TipRanks · 03/23 21:52
Percheron Therapeutics Launches Discounted Entitlement and Shortfall Offer
TipRanks · 03/16 01:52
Percheron Therapeutics Plans Issue of 50 Million Unquoted Options
TipRanks · 03/16 01:52
Percheron Therapeutics Plans Large Pro Rata Capital Raising on ASX
TipRanks · 03/16 01:47
Percheron Updates Timetable for $2.2m Entitlement Offer Ahead of 2026 Trials
TipRanks · 03/16 01:32
Percheron Therapeutics Launches Pro Rata Rights Offer at Discounted Issue Price
TipRanks · 03/15 23:25
Percheron Therapeutics Launches Discounted Entitlement Offer to Fund HMBD-002 Trial
TipRanks · 03/15 23:24
Percheron Therapeutics Plans Issue of 13.75 Million Unquoted Options
TipRanks · 03/13 07:45
More
Webull provides a variety of real-time PERCF stock news. You can receive the latest news about Percheron Therapeutics through multiple platforms. This information may help you make smarter investment decisions.
About PERCF
Percheron Therapeutics Limited is an Australia-based biotechnology company. The Company is focused on the development and commercialization of novel therapies for oncology and rare diseases. The Company’s lead program is HMBD-002, a monoclonal antibody targeting the immune checkpoint regulator, VISTA. HMBD-002 has completed a phase I clinical trial in patients with advanced cancer. HMBD-002 is a recombinant humanized monoclonal IgG4 antibody to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). VISTA is one of a number of novel immuno-oncology targets under investigation by pharmaceutical companies, with potential applications to a range of solid tumors and hematological malignancies.